{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:35:49Z","timestamp":1781825749821,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.ygyno.2013.03.027","type":"journal-article","created":{"date-parts":[[2013,4,3]],"date-time":"2013-04-03T02:32:01Z","timestamp":1364956321000},"page":"127-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: An international prospective cohort study"],"prefix":"10.1016","volume":"130","author":[{"given":"Yakir","family":"Segev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javaid","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lubinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Gronwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry T.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pal","family":"Moller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parviz","family":"Ghadirian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmaine","family":"Kim-Sing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Neuhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigha","family":"Senter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian F.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Karlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Narod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.03.027_bb0005","series-title":"Cancer incidence and mortality worldwide: IARC CancerBase No. 10","author":"Ferlay","year":"2010"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ygyno.2006.08.004","article-title":"The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study","volume":"104","author":"Beiner","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0015","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","article-title":"Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers","volume":"94","author":"Thompson","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0020","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium","volume":"91","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0025","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1086\/302853","article-title":"BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer","volume":"66","author":"Moslehi","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0030","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/gyno.2000.6082","article-title":"Risk of endometrial carcinoma associated with BRCA mutation","volume":"80","author":"Levine","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0035","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ctrv.2011.06.009","article-title":"Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review","volume":"38","author":"Iqbal","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0040","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1375\/twin.14.2.111","article-title":"Report of endometrial cancer in Australian BRCA1 and BRCA2 mutation-positive families","volume":"14","author":"Duffy","year":"2011","journal-title":"Twin Res Hum Genet"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0050","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(00)02677-5","article-title":"Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen","volume":"356","author":"Bergman","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0055","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0140-6736(05)71562-2","article-title":"Tamoxifen and risk of endometrial cancer","volume":"357","author":"Narod","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0060","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1525-1438.2007.01025.x","article-title":"The risk of developing uterine sarcoma after tamoxifen use","volume":"18","author":"Lavie","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0065","first-page":"1531","article-title":"BRCA germline mutations in women with uterine serous carcinoma\u2014still a debate","volume":"20","author":"Lavie","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0070","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.ejso.2006.03.032","article-title":"High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma","volume":"32","author":"Biron-Shental","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0075","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1006\/gyno.2000.6003","article-title":"Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?","volume":"79","author":"Goshen","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0080","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/cncr.27720","article-title":"BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma","volume":"119","author":"Pennington","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0378-5122(01)00213-4","article-title":"Menopause, hormone replacement therapy and cancer","volume":"39","author":"La Vecchia","year":"2001","journal-title":"Maturitas"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0090","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(05)66455-0","article-title":"Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study","volume":"365","author":"Beral","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0095","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/0140-6736(91)90417-N","article-title":"Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer","volume":"338","author":"Voigt","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0100","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/djn313","article-title":"Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers","volume":"100","author":"Eisen","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2013.03.027_bb0105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2007.09.031","article-title":"Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions","volume":"107","author":"Lancaster","year":"2007","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813001820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813001820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T13:22:42Z","timestamp":1539782562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813001820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0090825813001820"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.03.027","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: An international prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}